In recent years, social media have emerged as important spaces for commercial marketing of health tests, which can be used for the screening and diagnosis of otherwise generally healthy people. However, little is known about how health tests are promoted on social media, whether the [...]
Transvaginal mesh (TVM) surgeries were introduced as an innovative treatment for stress urine incontinency (SUI) and/or pelvic organ prolapse (POP) in 1996. Years after rapid adoption of these surgeries into practice, it emerged that TVM-associated adverse events were uncommon but potentially severe. This initiated global [...]
Corporations have been developing tactics to undermine independent science for decades. In the 1950s, on learning of the damaging effects of tobacco on health, the tobacco industry used campaigns of criticism to defend their products and the substantial revenue they were generating. Corporations could effectively [...]
Cancer physicians may have difficulty balancing the perceived need to interact with industry in modern cancer care while maintaining distance to minimise conflicts of interest. Further research is needed to assess management strategies in this area.
A systematic review investigated interactions with the pharmaceutical industry and how these might affect the clinical practice, knowledge and beliefs of cancer physicians. There is substantial evidence of frequent relationships between cancer physicians and the pharmaceutical industry in a range of high-income countries. More research [...]
Did you know the definition of high blood pressure (hypertension) in the United States was recently greatly expanded? Overnight, tens of millions of people were reclassified, leaving one in every two adults with a diagnosis of hypertension. The move has been welcomed by some but [...]
Experts developing guidelines to diagnose and treat cardiovascular diseases and diabetes are the least likely to disclose their financial ties with drug companies, a study led by Bond University in Queensland has found. The first study in Australia to examine undisclosed financial relationships between drug [...]
In September, the New York Times revealed that one of the world’s top cancer specialists had quietly received millions of dollars from drug and other companies. And what’s more, he’d failed to disclose the payments in many of his high-profile medical journal articles. A few months before [...]
There is global concern about the nature and extent of financial ties between pharmaceutical companies and health professionals, including those who develop influential clinical practice guidelines.3 In 2009, a landmark Institute of Medicine report on conflicts of interest acknowledged the importance of collaboration with industry, but [...]
